Duquesne Family Office LLC
Family OfficePosition in XENE — Xenon Pharmaceuticals Inc.
CIK 1536411
New York, NY
Position in XENE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$13,874,590
New position
Shares Held
238,600
first reported quarter
Ownership
0.247%
of shares outstanding
% of Portfolio
0.50%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Duquesne Family Office LLC holds $456,583,855 across 12 Biotechnology names. XENE ranks #10 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
1,154,090 | $188,716,796 | |
| 2 | NAMS |
NewAmsterdam Pharma Co N.V.
|
3,070,146 | $98,275,373 | |
| 3 | CAI |
Caris Life Sciences, Inc.
|
1,894,450 | $33,872,766 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
315,860 | $30,717,385 | |
| 5 | NUVB |
Nuvation Bio Inc.
|
4,539,800 | $19,475,742 | |
| 6 | BLTE |
Belite Bio, Inc
|
106,100 | $16,916,584 | |
| 7 | PTGX |
Protagonist Therapeutics, Inc
|
159,700 | $16,832,380 | |
| 8 | OLMA |
Olema Pharmaceuticals, Inc.
|
986,827 | $14,713,590 |
All Filings in XENE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13,874,590 | 238,600 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||